Back to Search
STEVEN SIENA, DO
DO
Student in an Organized Health Care Education/Training Program
NPI: 1770386419Individual
Specialties, Licenses & Credentials
Student in an Organized Health Care Education/Training ProgramPrimary
Student in an Organized Health Care Education/Training Program
Code: 390200000X
Research & Publications (20)
Malignant peritoneal mesothelioma: a multicenter study on 81 cases.
PMID 19635740·Ann Oncol·2010
4-observational
An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy.
PMID 18951651·Lung Cancer·2009
3-trial
Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy.
PMID 19189371·Cancer·2009
3-trial
Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.
PMID 19326424·Pediatr Blood Cancer·2009
8-other
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.
PMID 19223544·Cancer Res·2009
8-other
Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent.
PMID 19042053·Lung Cancer·2009
3-trial
Iron supplementation and erythropoiesis-stimulatory agents in the treatment of cancer anemia.
PMID 19152436·Cancer·2009
6-review
Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha.
PMID 18375891·J Clin Oncol·2008
2-rct
A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer.
PMID 18667394·Ann Oncol·2008
3-trial
Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer.
PMID 18757341·J Clin Oncol·2008
8-other
Iron supplementation during treatment with erythropoiesis-stimulating agents for cancer-related anemia.
PMID 18824846·Chemotherapy·2008
6-review
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
PMID 19001320·J Clin Oncol·2008
4-observational
Antitumor effect of allogeneic hematopoietic SCT in metastatic medulloblastoma.
PMID 18372908·Bone Marrow Transplant·2008
5-case
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
PMID 18316791·J Clin Oncol·2008
3-trial
Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial.
PMID 18077217·Lancet Oncol·2008
3-trial
Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study.
PMID 18854570·J Clin Oncol·2008
4-observational
First-line single-agent cetuximab in patients with advanced colorectal cancer.
PMID 18073221·Ann Oncol·2008
3-trial
An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy.
PMID 17785764·Ann Oncol·2008
3-trial
GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia.
PMID 17786611·Cytotherapy·2007
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 3003 W DR MARTIN LUTHER KING JR BLVD
TAMPA, FL 33607 - Phone
- (813) 554-8126
Quick Facts
- NPI
- 1770386419
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile